Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSFenretinide is a synthetic derivative of retinoic acid (Item No. 11017) and an inhibitor of dihydroceramide desaturase (IC50 = 2.32 µM).1 It promotes the generation of reactive oxygen species (ROS), the degradation of anti-apoptotic MCL-1, and the cleavage of pro-apoptotic PKCδ.2 At 5-20 µM, fenretinide selectively activates retinoic acid receptor γ (RARγ) and is reported to inhibit the growth of Caov-3, OVCAR-3, and SKOV3 ovarian cancer cells with IC50 values of 3.7, 6.9, and 8.2 µM, respectively.3,4 It also increases activity of serine palmitoyl transferase (SPT) by 1.75-fold and induces caspase-dependent apoptosis in BMEC cells (IC50 = 2.4 µM).5 Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake in isolated rat soleus muscle.6 In vivo, fenretinide (10 mg/ml in drinking water) reduces liver and soleus muscle neutral lipid content and inhibits high-fat diet-induced increases in dihydroceramide desaturase transcription.6
WARNING This product is not for human or veterinary use.
1. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. The Journal of Biological Chemisty 286(28), 24754-24764 (2011).
2. Role for PKCδ in fenretinide-
3. Classical and novel retinoids: Their targets in cancer therapy. Leukemia 16(4), 463-472 (2002).
4. Synthesis of flexible sulfur-
5. Ceramide signaling in fenretinide-
6. Fenretinide prevents lipid-